Americas Cancer Biologic Therapy Companies

Latest Americas Cancer Biological Therapy Companies Updates:

Dec 2023

Bristol-Myers SquibbReceived FDA approval for their Opdivo® (nivolumab) and Yervoy® (ipilimumab) combination therapy for first-line treatment of advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression.Partnered with academic institutions to explore the potential of their biologic therapies for treating additional cancer types and early-stage disease.

Roche Holding AG Announced positive Phase III data for their Tecentriq® (atezolizumab) in combination with chemotherapy for the treatment of advanced bladder cancer.Launched their Foundation® Medicine platform in Brazil, providing personalized genomic testing and treatment recommendations for cancer patients.

Merck & Co.Presented encouraging data at a major oncology conference on their Keytruda® (pembrolizumab) for the treatment of head and neck cancer.Collaborated with government agencies in Latin America to improve access to their cancer biologic therapies for underserved populations.

Eli Lilly and Company Received FDA approval for their Verzenio® (abemaciclib) as a first-line treatment for advanced HR-positive, HER2-negative breast cancer.Announced plans to expand their clinical trial portfolio in the Americas to include more diverse patient populations.

AbbVie Launched their Venclexta® (venetoclax) in combination with Rituximab for the treatment of chronic lymphocytic leukemia (CLL) in Argentina and Brazil.Partnered with patient advocacy groups to raise awareness about CLL and improve access to treatment options.

List of Americas Cancer Biological Therapy Key companies in the market

• Hoffmann-La Roche AG,


• GSK, Merck & Co.,


• Novartis International AG, Inc.,


• GlaxoSmithKline Plc,


• Bristol-Myers Squibb,


• Eli Lilly,


• Amgen Inc.,


• Spectrum Pharmaceuticals, Inc.,


• Seattle Genetics, Inc.,


• Celgene Corporation